aRandomization was stratified by histology (liposarcoma or leiomyosarcoma), number of prior therapies, and geographic region.
bDose determined by the investigator prior to randomization.
The FDA recognizes overall survival as the most reliable and preferred clinical endpoint in cancer trials4
References: 1. HALAVEN [package insert]. Nutley, NJ: Eisai Inc. 2. Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629-1637. 3. Data on file, Eisai Inc. 4. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. http://www.fda.gov/downloads/Drugs/guidancecomplianceregulatoryinformation/guidances/ucm071590.pdf. Published May 2007. Accessed January 15, 2016.